



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

Application Number	10/809,312
Filing Date	03/24/04
First Named Inventor	Lloyd A. Greene
Art Unit	1636
Examiner Name	to be assigned <i>Laura McGillem</i>
Attorney Docket Number	5199-69

Sheet 1 of 12

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
<i>JM</i>		Ahmed et al., BDNF enhances the differentiation but not the survival of CNS stem cell-derived neuronal precursors.	
<i>JM</i>		J. Neurosci., 15: 5765-5778, 1995	
<i>JM</i>		Angelastro et al., Identification of diverse nerve growth factor-regulated genes by serial analysis of gene expression (SAGE) profiling. 2000	
<i>JM</i>		Proc. Natl. Acad. Sci. USA, 97: 10424-10429, 2000	
<i>JM</i>		Angelastro et al., Characterization of a novel isoform of caspase-9 that inhibits apoptosis.	
<i>JM</i>		J. Biol. Chem., 276: 12190-12200, 2001	
<i>JM</i>		Ashrafi et al., Genome-wide RNAi analysis of Caenorhabditis elegans fat regulatory genes.	
<i>JM</i>		Nature, 421: 268-272, 2003	

Examiner Signature	<i>Laura McGillem</i>	Date Considered	3/22/2006
--------------------	-----------------------	-----------------	-----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

Application Number	10/809,312
Filing Date	03/24/04
First Named Inventor	Lloyd A. Greene
Art Unit	1636
Examiner Name	to be assigned Laura McGILLEM
Attorney Docket Number	5199-69

Sheet

2

of

12

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
JM		Barco et al., Expression of constitutively active CREB protein facilitates the late phase of long-term potentiation by enhancing synaptic capture.	
JM		Cell, 108: 689-703, 2002	
JM		Bhatia, AC133 expression in human stem cells.	
JM		Leukemia, 15: 1685-1688, 2001	
JM		Bieri et al., Abnormal nerve conduction studies in mice expressing a mutant form of the POU transcription factor, SCIP.	
JM		J. Neurosci. Res., 50: 821-828, 1997	
JM		Billy et al., Specific interference with gene expression induced by long, double-strand RNA in mouse embryonal teratocarcinoma cell lines.	
JM		Proc. Natl. Acad. Sci. USA, 98: 14428-14433, 2001	

Examiner Signature	Laura McGILLEM	Date Considered	3/22/2006
--------------------	----------------	-----------------	-----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

Application Number	10/809,312
Filing Date	03/24/04
First Named Inventor	Lloyd A. Greene
Art Unit	1636
Examiner Name	to be assigned LAURA MCGILLEN
Attorney Docket Number	5199-69

Sheet 3 of 12

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
LM		Burstein and Greene, Evidence for RNA synthesis-dependent and -independent pathways in stimulation of neurite outgrowth by nerve growth factor.	
LM		Proc. Natl. Acad. Sci. USA, 75: 6059-6063, 1978	
Not provided Not considered		Cottrell et al., Silence of the strands: RNA interference in eukaryotic pathogens.	
		Trends Microbiol., 11: 37-43, 2003 (N/A)	
LM		Dawson and Ginty, CREB family transcription factors inhibit neuronal suicide.	
LM		Nat. Med., 8: 450-451, 2002	
LM		Dicicco-Bloom et al., The PACAP ligand/receptor system regulates cerebral cortical neurogenesis.	
LM		Ann. N. Y. Acad. Sci., 865: 274-289, 1998	

Examiner Signature	Laura McGillem	Date Considered	3/22/2006
--------------------	----------------	-----------------	-----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

Application Number	10/809,312
Filing Date	03/24/04
First Named Inventor	Lloyd A. Greene
Art Unit	1636
Examiner Name	to be assigned LAURA MCGILLEM
Attorney Docket Number	5199-69

Sheet 4

of

12

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
LM		Escobar et al., RNAi-mediated oncogene silencing confers resistance to crown gall tumorigenesis.	
LM		Proc. Natl. Acad. Sci. USA, 98: 13437-13442, 2001	
LM		Finkeiner et al., CREB: a major mediator of neuronal neurotrophin responses.	
LM		Neuron, 19: 1031-1047, 1997.	
LM		Fukumitsu et al., Simultaneous expression of brain-derived neurotrophic factor and neurotrophin-3 in Cajal-Retzius, subplate and ventricular	
LM		progenitor cells during early development stages of the rat cerebral cortex.	
LM		Neuroscience, 84: 115-127, 1998,	
LM		Gage, F.H., Mammalian neural stem cells.	
LM		Science, 287: 1433-1438, 2000.	

Examiner Signature	Laura McGill	Date Considered	3/22/2006
--------------------	--------------	-----------------	-----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		<b>Complete if Known</b>			
		Application Number	10/809,312		
		Filing Date	03/24/04		
		First Named Inventor	Lloyd A. Greene		
		Art Unit	1636		
		Examiner Name	to be assigned LAURA McGILLER		
Sheet	5	of	12	Attorney Docket Number	5199-69

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
LM		Ghosh and Greenberg, Distinct roles for bFGF and NT-3 in the regulation of cortical neurogenesis.	
LM		Neuron, 15: 89-103, 1995.	
LM		Greene et al., Establishment of a noradrenergic clonal line of rat adrenal pheochromocytoma cells which respond to nerve growth factor.	
LM		Proc. Natl. Acad. Sci. USA, 73: 2424-2428, 1998.	
Not provided Not considered		Greene et al., Culture and Experimental Use of the PC12 Rat Pheochromocytoma Cell Line. In: Culturing Nerve Cells, 2nd ed., Goslin, G.K., ed.	
		(Cambridge, MA: The MIT Press, 1998) pp. 161-187. (N/A)	
LM		Gunning et al., Differential and synergistic actions of nerve growth factor and cyclic AMP in PC12 cells.	
LM		J. Cell Biol., 89: 240-245, 1981.	
LM		Hansen et al., Mouse Atf5: molecular cloning of two novel mRNAs, genomic organization, and odorant sensory neuron localization.	
LM		Genomics, 80: 344-350, 2002.	

Examiner Signature	<i>Laura McGiller</i>	Date Considered	3/22/2006
--------------------	-----------------------	-----------------	-----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

Application Number	10/809,312
Filing Date	03/24/04
First Named Inventor	Lloyd A. Greene
Art Unit	1636
Examiner Name	to be assigned: LAURA M. G. LIEB
Attorney Docket Number	5199-69

Sheet

6

of

12

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
LM		Julius et al., Q vectors, bicistronic retroviral vectors for gene transfer.	
LM		Biotechniques, 28: 702-708, 2000	
LM		Kintner, C., Neurogenesis in embryos and in adult neural stem cells.	
LM		J. Neurosci., 22: 639-643, 2002	
LM		Krylov et al., Extending dimerization interfaces: the bZIP basic region can form a coiled coil.	
LM		EMBO J., 14: 5329-5337, 1995	
LM		Kukekov et al., A nestin-negative precursor cell from the adult mouse brain gives rise to neurons and glia.	
LM		Glia, 21: 399-407, 1997 (N/A)	
LM		Kukekov et al., Multipotent stem / progenitor cells with similar properties arise from two neurogenic regions of adult human brain.	
LM		Exp. Neurol., 156: 333-344, 1999	

Examiner  
Signature

Laura M. G. Lieb

Date  
Considered

3/23/2006

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English Language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

Sheet <u>7</u> of <u>12</u>	Application Number	10/809,312
	Filing Date	03/24/04
	First Named Inventor	Lloyd A. Greene
	Art Unit	1636
	Examiner Name	to be assigned <u>LAURA MCGILLER</u>
Attorney Docket Number		5199-69

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
<i>LM</i>		Laywell et al., Multipotent neurospheres can be derived from forebrain subependymal zone and spinal cord of adult mice after protracted	
<i>LM</i>		postmortem intervals.	
<i>LM</i>		Exp. Neurol., 156: 430-433, 1999.	
<i>LM</i>		Laywell et al., Identification of a multipotent astrocytic stem cell in the immature and adult mouse brain.	
<i>LM</i>		Proc. Natl. Acad. Sci. USA, 97: 13883-13888, 2000.	
<i>LM</i>		Lee et al., Posttranslational modification of class III beta-tubulin.	
<i>LM</i>		Proc. Natl. Acad. Sci. USA, 87: 7195-7199, 1990	
<i>LM</i>		Lendahl et al., CNS stem cells express a new class of intermediate filament protein.	
<i>LM</i>		Cell, 60: 585-595, 1990	

Examiner Signature	<u>Laura McGiller</u>	Date Considered	<u>3/23/2006</u>
--------------------	-----------------------	-----------------	------------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		<b>Complete if Known</b>	
		Application Number	10/809,312
		Filing Date	03/24/04
		First Named Inventor	Lloyd A. Greene
		Art Unit	1636
		Examiner Name	<del>to be assigned</del> LAURA MCGILLEN
Sheet 8	of 12	Attorney Docket Number	5199-69

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
LM		Li et al., Neuronal differentiation of precursors in the neocortical ventricular zone is triggered by BMP.	
LM		J. Neurosci., 18: 8853-8862, 1998	
LM		Lonze et al., Apoptosis, axonal growth defects, and degeneration of peripheral neurons in mice lacking CREB.	
LM		Neuron, 34: 371-385, 2002	
LM		Lu et al., The herpesvirus transactivator VP16 mimics a human basic domain leucine zipper protein, human, in its interaction with HCF.	
LM		J. Virol., 72: 6291-6297, 1998	
LM		Mendelsohn et al., Stromal cells mediate retinoid-dependent functions essential for renal development.	
LM		Development, 126: 1139-1148, 1999	
LM		Moitra et al., Life without white fat: a transgenic mouse.	
LM		Genes Dev., 12: 3168-3181, 1998	

Examiner Signature	<i>Laura McGillen</i>	Date Considered	3/23/2006
--------------------	-----------------------	-----------------	-----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

Application Number	10/809,312
Filing Date	03/24/04
First Named Inventor	Lloyd A. Greene
Art Unit	1636
Examiner Name	to be assigned Laura McGILLEM
Attorney Docket Number	5199-69

Sheet

9

of

12

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
JH		Moll et al., Attractive interhelical electrostatic interactions in the proline- and acidic-rich region (PAR) leucine zipper subfamily preclude	
JH		preclude heterodimerization with other basic leucine zipper subfamilies.	
JH		J. Biol. Chem., 275: 34826-34832, 2000 ,	
JH		Nikolae et al., Parc. A cytoplasmic anchor for p53.	
JH		Cell, 112: 29-40, 2003 ,	
JH		Nishizawa and Nagata, cDNA clones encoding leucine-zipper proteins which interact with G-CSF gene promoter element 1- binding protein.	
JH		FEBS Lett., 299: 36-38, 1992.,	
JH		Pati et al., Human Cdc34 and Rad6B ubiquitin-conjugating enzymes target repressors of cyclic AMP-induced transcription for proteolysis.	
JH		Mol. Cell Biol., 19: 5001-5013, 1999.,	

Examiner Signature	<i>Laura McGillem</i>	Date Considered	3/23/2004
--------------------	-----------------------	-----------------	-----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		<b>Complete if Known</b>	
		Application Number	10/809,312
		Filing Date	03/24/04
		First Named Inventor	Lloyd A. Greene
		Art Unit	1636
		Examiner Name	to be assigned LAURA MCGILLEM
Sheet 10	of 12	Attorney Docket Number	5199-69

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
LM		Persengiev et al., Inhibition of apoptosis by ATFx: a novel role for a member of the ATF/CREB family of mammalian bZIP transcription factors.	
LM		Genes Dev., 16: 1806-1814, 2002.	
LM		Peters et al., ATF-7, a novel bZIP protein, interacts with the PRL-1 protein-tyrosine phosphatase.	
LM		J. Biol. Chem., 276: 13718-13726, 2001,	
LM		Placzek and Furley, Patterning cascades in the neural tube. Neural development.	
LM		Curr. Biol. 6: 526-529, 1996.	
LM		Schuermans and Guillemot, Molecular mechanisms underlying cell fate specification in the developing telencephalon.	
LM		Curr. Opin. Neurobiol., 12: 26-34, 2002.	
LM		Takemura et al., In situ localization of tau mRNA in developing rat brain.	
LM		Neuroscience, 44: 393-407, 1991.	

Examiner Signature	<i>Laura McGillem</i>	Date Considered	3/23/2006
--------------------	-----------------------	-----------------	-----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

Sheet 11 of 12	Application Number	10/809,312
	Filing Date	03/24/04
	First Named Inventor	Lloyd A. Greene
	Art Unit	1636
	Examiner Name	<del>to be assigned</del> Laura McGILLUM
Attorney Docket Number		5199-69

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
SM		Towbin et al., Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications.	
SM		Proc. Natl. Acad. Sci. USA 76: 4350-4354, 1979	
SM		Uchida et al., Direct isolation of human central nervous system stem cells.	
SM		Proc. Natl. Acad. Sci. USA, 97: 14720-14725, 2000,	
SM		Vinson et al., Dimerization specificity of the leucine zipper-containing bZIP motif on DNA binding: prediction and rational design.	
SM		Genes Dev., 7: 1047-1058, 1993	
SM		Waxman and Bennett, Relative conduction velocities of small myelinated and nonmyelinated fibres in the central nervous system.	
SM		Nature New Biol., 238: 217, 1972	
SM		Wilda et al., Killing of leukemic cells with a BCR/ABL fusion gene RNA interference (RNAi).	
SM		Oncogene, 21: 5716-5724, 2002,	

Examiner Signature	Laura McGILLUM	Date Considered	3/23/2006
--------------------	----------------	-----------------	-----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

Sheet 12 of 12

Application Number	10/809,312
Filing Date	03/24/04
First Named Inventor	Lloyd A. Greene
Art Unit	1636
Examiner Name	to be assigned <i>Laura McGILVER</i>
Attorney Docket Number	5199-69

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
<i>LM</i>		Yin et al., AC133, a novel marker for human hematopoietic stem and progenitor cells.	
<i>LM</i>		Blood, 90: 5002-5012, 1997,	
<i>LM</i>		Yu et al., AC133-2, a novel isoform of human AC133 stem cell antigen.	
<i>LM</i>		J. Biol. Chem., 277: 20711-20716, 2002.	
<i>Not provided Not considered Not provided Not considered</i>		Beers and Berkow, eds., The Merck Manual of Diagnosis and Therapy, 17th ed. (N/A)	
		Whitehouse Station, NJ: Merck Research Laboratories, 1999, Chap. 183 (N/A)	
		Bodansky, M., Principles of Peptide Synthesis, New York: Springer-Verlag New York, Inc., 1984 (N/A)	
		Modern Techniques of Peptide and Amino Acid Analysis, New York: John Wiley & Sons, 1981 (N/A)	

Examiner Signature	<i>Laura McGilver</i>	Date Considered	3/23/2006
--------------------	-----------------------	-----------------	-----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.